Trials / Completed
CompletedNCT01461018
Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)
A Multicenter Study of Long-Term Clinical Outcomes of Immune Globulin Subcutaneous (Human) (SCIG) IgPro20 in Subjects With Primary Immunodeficiency
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- CSL Behring · Industry
- Sex
- All
- Age
- 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the long-term efficacy, tolerability, and safety of IgPro20 in subjects with primary immunodeficiency (PID) as an extension to the preceding follow-up study ZLB07\_001CR (NCT01458171).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Immune globulin subcutaneous (Human) | IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2011-10-27
- Last updated
- 2014-12-02
Locations
9 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01461018. Inclusion in this directory is not an endorsement.